Identification
NameTRIAZOLOPYRIMIDINE
Accession NumberDB04669
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightAverage: 382.237
Monoisotopic: 381.046332125
Chemical FormulaC17H14BrN6
InChI KeyYWBFPKPWMSWWEA-UHFFFAOYSA-O
InChI
InChI=1S/C17H13BrN6/c18-14-3-1-2-13(8-14)15-9-16(24-17(23-15)21-11-22-24)20-10-12-4-6-19-7-5-12/h1-9,11H,10H2,(H,20,21,22,23)/p+1
IUPAC Name
7-(3-bromophenyl)-5-[(pyridin-4-ylmethyl)amino]-3H-4λ⁵-[1,2,4]triazolo[1,5-a]pyrimidin-4-ylium
SMILES
BrC1=CC=CC(=C1)C1=NC2=[N+](NC=N2)C(NCC2=CC=NC=C2)=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Cyclin-dependent kinase 2ProteinunknownNot AvailableHumanP24941 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis Reference

Nicole Bru-Magniez, Eric Nicolai, Jean-Marie Teulon, "Triazolopyrimidine derivatives which are angiotensin II receptor antagonists processes for preparing them and pharmaceutical compositions containing them." U.S. Patent US5217973, issued March, 1964.

US5217973
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00529 mg/mLALOGPS
logP0.7ALOGPS
logP0.66ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)8.77ChemAxon
pKa (Strongest Basic)5.02ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area70.59 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity117.91 m3·mol-1ChemAxon
Polarizability36.25 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9748
Blood Brain Barrier+0.9455
Caco-2 permeable-0.5096
P-glycoprotein substrateNon-substrate0.6098
P-glycoprotein inhibitor INon-inhibitor0.8708
P-glycoprotein inhibitor IINon-inhibitor0.5653
Renal organic cation transporterNon-inhibitor0.6254
CYP450 2C9 substrateNon-substrate0.8951
CYP450 2D6 substrateNon-substrate0.8356
CYP450 3A4 substrateNon-substrate0.574
CYP450 1A2 substrateInhibitor0.8209
CYP450 2C9 inhibitorNon-inhibitor0.7096
CYP450 2D6 inhibitorNon-inhibitor0.7801
CYP450 2C19 inhibitorInhibitor0.5374
CYP450 3A4 inhibitorInhibitor0.5
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8303
Ames testNon AMES toxic0.6724
CarcinogenicityNon-carcinogens0.8114
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5969 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6942
hERG inhibition (predictor II)Non-inhibitor0.6343
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassDiazines
Direct ParentPhenylpyrimidines
Alternative ParentsTriazolopyrimidines / Secondary alkylarylamines / Bromobenzenes / Aminopyrimidines and derivatives / Pyridines and derivatives / Aryl bromides / Triazoles / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds
Substituents4-phenylpyrimidine / 5-phenylpyrimidine / Triazolopyrimidine / Aminopyrimidine / Bromobenzene / Halobenzene / Secondary aliphatic/aromatic amine / Benzenoid / Monocyclic benzene moiety / Aryl bromide
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsorganobromine compound, aminoalkylpyridine, triazolopyrimidines (CHEBI:47355 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Metal ion binding
Specific Function:
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synt...
Gene Name:
CDK2
Uniprot ID:
P24941
Uniprot Name:
Cyclin-dependent kinase 2
Molecular Weight:
33929.215 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Drug created on September 11, 2007 11:49 / Updated on June 11, 2017 20:57